Diversification of Research and Development Financing Methods
First written in FY2022. 9 of 11 entries say "Advanced", first in FY2023-Q1. Latest entry: 2026-06-17.
15 other companies' latest entry also says "Advanced".
- FY2026-H1AdvancedAnnual report
「Funds provided by financing activities amounted to ¥28.376 million, compared with ¥14.280 million used in the same period of the previous year. This was mainly because proceeds of ¥38.400 million from the issuance of shares exceeded payments of ¥10.024 million for the repayment of long-term borrowings.」
The company recorded proceeds of ¥38.400 million from the issuance of shares and conducted an equity issuance as a means of funding R&D and other activities. - FY2025-H1SoftenedAnnual report
「Establishment of a US subsidiary (Boston) 100,000 The fiscal year ending March 2026 and thereafter (—)」
Regarding the use of listing proceeds, the establishment of the US subsidiary in Boston was postponed from the fiscal year ending March 2024 to the fiscal year ending March 2026 and thereafter. - FY2024-Q3AdvancedAnnual report
「This was attributable to increases of ¥29.088 million each in capital stock and capital surplus through the exercise of stock acquisition rights, and the recording of a quarterly net loss of ¥955.474 million.」
The exercise of stock acquisition rights increased both capital stock and capital surplus by ¥29.088 million. - FY2024-Q2AdvancedAnnual report
「The undrawn balance and other details relating to borrowings under the overdraft agreement at the end of the second quarter accounting period are as follows. Overdraft limit: ¥1,000 million; drawn balance: ¥0 million; available balance: ¥1,000 million.」
The overdraft limit as a source of working capital funding increased from ¥500 million at the end of the previous fiscal year to ¥1,000 million. In addition, the exercise of stock acquisition rights increased both capital stock and capital surplus by ¥26.588 million. - FY2024-Q1AdvancedAnnual report
「The undrawn balance and other details relating to borrowings under the overdraft agreement at the end of the first quarter accounting period are as follows.」
The company established a bank overdraft facility with a limit of ¥500 million to efficiently fund working capital. In addition, the exercise of stock acquisition rights during the quarter increased both capital stock and capital surplus by ¥2.950 million, and additional exercises took place in July. - FY2023AdvancedAnnual report
「Total net assets at the end of the fiscal year were ¥1,950.373 million, an increase of ¥1,206.019 million from the end of the previous fiscal year. This was attributable to increases of ¥557.919 million each in capital stock and capital surplus through a public offering and the exercise of stock acquisition rights, as well as the recording of net income of ¥90.181 million.」
In addition to the public offering, the exercise of stock acquisition rights progressed, increasing both capital stock and capital surplus by ¥557.919 million and bringing net assets to ¥1,950.373 million. - FY2023-Q3AdvancedAnnual report
「Total net assets at the end of the third quarter accounting period were ¥2,041.624 million, an increase of ¥1,297.270 million from the end of the previous fiscal year. This was attributable to increases of ¥547.844 million each in capital stock and capital surplus through a public offering and the exercise of stock acquisition rights, as well as the recording of quarterly net income of ¥201.582 million.」
In addition to the public offering, funding through the exercise of stock acquisition rights progressed, increasing both capital stock and capital surplus by ¥547.844 million at the end of the third quarter accounting period. - FY2023-Q1AdvancedAnnual report
「The company was listed on the Tokyo Stock Exchange Growth Market on 23 June 2022. The public offering conducted in connection with the listing increased the number of issued shares by 2,500,000 and increased both capital stock and capital surplus by ¥540.5 million.」
The company conducted a public offering, increasing the number of issued shares by 2,500,000 and increasing both capital stock and capital surplus by ¥540.5 million. - FY2022First statedAnnual report
「The company will diversify funding sources for R&D through the necessary funds raised in the equity market, bank loans, subsidies and other means.」
The company plans to secure R&D funding through a combination of equity financing, borrowings and subsidies.